A Multi-arm Phase 3 Randomized Placebo Controlled Double Blind Clinical Trial to Investigate the Efficacy and Safety of BMS-663068/GSK3684934 in Heavily Treatment Experienced Subjects Infected with Multi-drug Resistant HIV-1
Active, no longer recruiting
Phase of Trial: Phase III
Latest Information Update: 20 Oct 2017
At a glance
- Drugs Fostemsavir (Primary)
- Indications HIV-1 infections
- Focus Registrational; Therapeutic Use
- Sponsors Bristol-Myers Squibb; GlaxoSmithKline; ViiV Healthcare
- 10 Jun 2017 Biomarkers information updated
- 28 Apr 2017 Planned End Date changed from 1 Aug 2018 to 15 Apr 2020.
- 28 Apr 2017 Planned primary completion date changed from 1 Sep 2016 to 1 Apr 2020.